Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake

Rhea-AI Filing Summary

Unicycive Therapeutics, Inc. is reported to have 4,856,259 shares of its common stock beneficially owned by Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, under an amended Schedule 13G. This position represents 9.99% of the common stock based on 27,855,257 shares outstanding as of August 12, 2026.

The reported stake includes 550,000 outstanding common shares and an additional 4,306,259 shares issuable upon conversion of Series A-3, A-4 and A-5 Convertible Preferred Stock underlying Tranche A, B and C warrants that are exercisable within 60 days. These preferred shares include blocking provisions that prevent conversion if it would result in ownership above 9.99%, although the reported share numbers reflect full convertibility without applying this cap.

Key Figures

Beneficial ownership: 4,856,259 shares Ownership percentage: 9.99% Shares outstanding: 27,855,257 shares +4 more

7 metrics

Beneficial ownership 4,856,259 shares Total Unicycive common stock beneficially owned by Vivo Opportunity entities

Ownership percentage 9.99% Portion of Unicycive common stock class beneficially owned

Shares outstanding 27,855,257 shares Unicycive common stock outstanding as of August 12, 2026

Common shares held 550,000 shares Outstanding Unicycive common stock held by Vivo Opportunity

Shares from Series A-3 conversion 1,280,239 shares Common stock issuable upon conversion of 6,913.28952 Series A-3 Preferred underlying Tranche A Warrants

Shares from Series A-4 conversion 1,163,854 shares Common stock issuable upon conversion of 6,866.73506 Series A-4 Preferred underlying Tranche B Warrants

Shares from Series A-5 conversion 1,862,166 shares Common stock issuable upon conversion of 13,780.0247 Series A-5 Preferred underlying Tranche C Warrants

Key Terms

beneficially owned, Convertible Preferred Stock, Tranche A Warrants, blocking provisions, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: The shares reported"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Convertible Preferred Stock financial

"shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

Tranche A Warrants financial

"Series A-3 Preferred Stock underlying Tranche A Warrants that are exercisable"

blocking provisions financial

"contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock"

sole voting power financial

"5 | Sole Voting Power 4,856,259.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

What percentage of Unicycive Therapeutics (UNCY) does Vivo Opportunity report owning?

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 9.99% of Unicycive Therapeutics’ common stock, based on 27,855,257 shares outstanding as of August 12, 2026.

How many Unicycive Therapeutics (UNCY) shares does Vivo Opportunity beneficially own?

Vivo Opportunity reports beneficial ownership of 4,856,259 shares of Unicycive common stock, including issued shares and shares issuable upon conversion of several series of convertible preferred stock underlying warrants exercisable within 60 days.

What portion of Vivo Opportunity’s UNCY position is currently common stock versus convertible securities?

The position includes 550,000 shares of common stock and 4,306,259 shares issuable upon conversion of Series A-3, A-4 and A-5 Convertible Preferred Stock, which are tied to Tranche A, B and C warrants that are exercisable within 60 days.

What is the share count basis for Vivo Opportunity’s 9.99% ownership in UNCY?

The 9.99% ownership is calculated using 27,855,257 shares of Unicycive common stock outstanding as of August 12, 2026, as reported in Unicycive’s Quarterly Report on Form 10-Q.

Are there ownership limits affecting Vivo Opportunity’s convertible preferred stock in UNCY?

Yes. The Series A-3, A-4 and A-5 Convertible Preferred Stock include blocking provisions that prevent conversion if it would give the holder more than 9.99% of Unicycive’s voting securities, though the reported amounts assume full conversion.

Who holds the Unicycive Therapeutics (UNCY) shares reported by Vivo Opportunity?

All securities are held of record by Vivo Opportunity Fund Holdings, L.P., with Vivo Opportunity, LLC acting as its general partner, and each reporting person lists sole voting and dispositive power over 4,856,259 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:20 PM Accepted by SEC EDGAR 08/14/2026 - 04:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Unicycive Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

90466Y202

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90466Y202

1

Names of Reporting Persons

Vivo Opportunity Fund Holdings, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,856,259.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,856,259.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,856,259.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents (i) 550,000 shares of common stock, par value $0.001 per share (the "Common Stock") of Unicycive Therapeutics, Inc. (the "Issuer"), (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share (the "Series A-3 Preferred Stock") underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Convertible Preferred Stock, par value $0.001 per share (the "Series A-4 Preferred Stock") underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Convertible Preferred Stock, par value $0.001 per share (the "Series A-5 Preferred Stock") underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent of class is based on 27,855,257 shares of Common Stock outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2026. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.

SCHEDULE 13G

CUSIP Number(s): 90466Y202

1

Names of Reporting Persons

Vivo Opportunity, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,856,259.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,856,259.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,856,259.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents (i) 550,000 shares of Common Stock of the Issuer, (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent of class is based on 27,855,257 shares of Common Stock outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 16, 2026. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Unicycive Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1975 W. El Camino Real, Suite 204, Mountain View, CA 94040
Item 2.
(a)	Name of person filing: (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.
(c)	Citizenship: (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 90466Y202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The shares reported in this Schedule 13G amendment represent (i) 550,000 shares of Common Stock of the Issuer, (ii) 1,280,239 shares of Common Stock issuable upon conversion of 6,913.28952 shares of Series A-3 Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (iii) 1,163,854 shares of Common Stock issuable upon conversion of 6,866.73506 shares of Series A-4 Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iv) 1,862,166 shares of Common Stock issuable upon conversion of 13,780.0247 shares of Series A-5 Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.
(b)	Percent of class: Vivo Opportunity Fund Holdings, L.P. 9.99%* Vivo Opportunity, LLC 9.99%*
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Opportunity Fund Holdings, L.P. 4,856,259 Vivo Opportunity, LLC 4,856,259
	(ii) Shared power to vote or to direct the vote: Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Opportunity Fund Holdings, L.P. 4,856,259 Vivo Opportunity, LLC 4,856,259
	(iv) Shared power to dispose or to direct the disposition of: Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Opportunity Fund Holdings, L.P.

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:	08/14/2026

Vivo Opportunity, LLC

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	08/14/2026